![Alina Frecautan (Romania), undergraduate study program International Business, Romania | UNIVERSITY OF RIJEKA, FACULTY OF ECONOMICS AND BUSINESS Alina Frecautan (Romania), undergraduate study program International Business, Romania | UNIVERSITY OF RIJEKA, FACULTY OF ECONOMICS AND BUSINESS](https://www.efri.uniri.hr/upload/katalog/2019-4-4_alina_frecautan_romania_2nd_year_of_undergraduate_.jpg)
Alina Frecautan (Romania), undergraduate study program International Business, Romania | UNIVERSITY OF RIJEKA, FACULTY OF ECONOMICS AND BUSINESS
Implant & Aesthetic Academy - *October Study Club announcement* Join us on Otocber 6th at 18h30 for Dr Alina Krivitsky Aalam! Dr. Alina Krivitsky Aalam graduated with a BS in Dental Hygiene,
![Yakup Ergün on X: "#ESMO23 ALINA trial: Adjuvant Alectinib vs Chemotherapy 3y DFS Stage 1B➡️92.3 vs 71.6% (HR:0.21) Stage 2➡️95.6 vs 66.3% (HR:0.24) Stage 3➡️92.7 vs 60.7% (HR:0.25) Practice-changing study💥💥 Presented by Yakup Ergün on X: "#ESMO23 ALINA trial: Adjuvant Alectinib vs Chemotherapy 3y DFS Stage 1B➡️92.3 vs 71.6% (HR:0.21) Stage 2➡️95.6 vs 66.3% (HR:0.24) Stage 3➡️92.7 vs 60.7% (HR:0.25) Practice-changing study💥💥 Presented by](https://pbs.twimg.com/media/F8-NhF2X0AAJZsy.jpg)
Yakup Ergün on X: "#ESMO23 ALINA trial: Adjuvant Alectinib vs Chemotherapy 3y DFS Stage 1B➡️92.3 vs 71.6% (HR:0.21) Stage 2➡️95.6 vs 66.3% (HR:0.24) Stage 3➡️92.7 vs 60.7% (HR:0.25) Practice-changing study💥💥 Presented by
![Alectinib in ALINA Trial: Phase III Adjuvant Therapy Study for Stage IB to IIIA ALK+ Non-Small Cell Lung Cancer Josin... Alectinib in ALINA Trial: Phase III Adjuvant Therapy Study for Stage IB to IIIA ALK+ Non-Small Cell Lung Cancer Josin...](https://oncologytubecom.cdn.ypt.me/videos/video_231124064326_vf9ce/video_231124064326_vf9ce.jpg?cache=17008271131700827113)
Alectinib in ALINA Trial: Phase III Adjuvant Therapy Study for Stage IB to IIIA ALK+ Non-Small Cell Lung Cancer Josin...
![Giannis Mountzios on X: "#ESMO23: Much awaited ALINA trial Alectinib up to 2yrs vs chemoX4 in ALK+ resected IB-IIIA #NSCLC by unique @bensolomon1 • N=130/127 • mFUP=27.8m • mDFS=NE vs41.3m, HR=0.24! • Giannis Mountzios on X: "#ESMO23: Much awaited ALINA trial Alectinib up to 2yrs vs chemoX4 in ALK+ resected IB-IIIA #NSCLC by unique @bensolomon1 • N=130/127 • mFUP=27.8m • mDFS=NE vs41.3m, HR=0.24! •](https://pbs.twimg.com/media/F8-MaD5WkAEHU1r.jpg:large)
Giannis Mountzios on X: "#ESMO23: Much awaited ALINA trial Alectinib up to 2yrs vs chemoX4 in ALK+ resected IB-IIIA #NSCLC by unique @bensolomon1 • N=130/127 • mFUP=27.8m • mDFS=NE vs41.3m, HR=0.24! •
![Melancholy and the Otherness of God: A Study in the Genealogy, Hermeneutics, and Therapeutics of Depression : Feld, Alina N.: Amazon.es: Libros Melancholy and the Otherness of God: A Study in the Genealogy, Hermeneutics, and Therapeutics of Depression : Feld, Alina N.: Amazon.es: Libros](https://m.media-amazon.com/images/I/7150-ZTYg3L._AC_UF1000,1000_QL80_.jpg)